logo
The Pakistan Credit Rating Agency Limited
Press Release

Date
14-Sep-22

Analyst
Muhammad Azmat Shaheen
azmat.shaheen@pacra.com
+92-42-35869504
www.pacra.com

Applicable Criteria

Related Research

Disclaimer
This press release is being transmitted for the sole purpose of dissemination through print/electronic media. The press release may be used in full or in part without changing the meaning or context thereof with due credit to PACRA

PACRA Assigns Initial Entity Ratings to Bikiya Industries Private Limited

Rating Type Entity
Current
(14-Sep-22 )
Action Initial
Long Term BB
Short Term A3
Outlook Stable
Rating Watch -

Bikiya Industries Private Limited ('BIPL' or the 'Company') is family owned business with majority stake lying with Mr. Muhammad Saleem Bikiya. BIPL is among the top five manufacturer of tissue paper. Over the period, the Company has established its brand name "TUX" amongst the leading tissue providers in Pakistan. The production of the segment is directly linked with the demand of food products and consumer goods. considering the higher demand, the utilization level has remained on higher side. Going forward, considering optimum utilization level and further strengthening of market share, the Company is planning to expand its operations. Currently, the average market share of the Company stood at ~5% in the tissue paper industry. The CEO/owner has an extensive knowledge of industry trends and tissue business with overall 30 years of experience. While the Management has a well understanding of business and operational efficiencies. The governance structure is considered weak due to the absence of a formal board structure, board committees, and independent oversight, furthermore external auditors are not QCR rated and denote room for improvement. The Company structure is not complex making management of operations an easy and timely task with one head office and two production offices.
The financial risk profile of the Company is considered adequate. The Company and its brand are still under development phase, there are higher operating expenses since past four fiscal years resulting in negative after tax profits. Revenue for the Company during 9MFY22 stood at PKR 561mln (FY21: PKR 510mln) with net profit margin of -3.3% (FY21: -9.1%). The net working capital days fall on higher side, depicting higher utilization of running finance resultantly, the leveraging of the company remained on higher side during the period under review. The profitability of the Company would remain under pressure considering developmental expenses and higher finance cost. However, financial commitments from sponsors exist in times of need.
The ratings are dependent on the Company’s ability to sustain its position amidst changing business environment and management’s ability to run the operations of the Company optimally. With the upcoming growth in firm’s business & volumes; prudent financial discipline and implementation of a stringent control environment shall remain imperative.

About the Entity
BIPL was established in 2014 with a share capital of PKR 50mln. Mr. Saleem Bikiya has 80% shareholding while his sons Mr. Usman Bikiya and Mr. Muhammad Bilal has 10% shareholding each. BIPL deals in five products namely i) Pop-up Tissue Box, ii) Toilet Roll, iii) Pop-up Mini Tissue, iv) Hand Towel and v) Party Pack having a widespread customer base. The Company sells to northern, central and southern regions of Pakistan. About 58% of customer base of BIPL is located in southern region with respect to geographical concentration.

The primary function of PACRA is to evaluate the capacity and willingness of an entity to honor its obligations. Our ratings reflect an independent, professional and impartial assessment of the risks associated with a particular instrument or an entity. PACRA's comprehensive offerings include instrument and entity credit ratings, insurer financial strength ratings, fund ratings, asset manager ratings and real estate gradings. PACRA opinion is not a recommendation to purchase, sell or hold a security, in as much as it does not comment on the security's market price or suitability for a particular investor.